Sarra L.
- Country
- France
- Department
- Medical oncology
Research Overview
- Efficacy and Safety Evaluation of TTX-030 and Chemotherapy With or Without Budigalimab in Untreated Metastatic Pancreatic Adenocarcinoma
- Phase 3 Randomized Study of Zanidatamab Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Phase 3 Study of PF-07220060 and Letrozole Versus CDK4/6 Inhibitors and Letrozole in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Data & Insights
Has run more than one trial at 37 of 180 partner sites.
Specializations
Oncology Research Focus
This investigator specializes in clinical research addressing advanced forms of cancer, with particular emphasis on metastatic disease treatment strategies.
- Pancreatic adenocarcinoma
- Advanced breast cancer
The investigator explores innovative therapeutic approaches for patients with metastatic conditions.
Therapeutic Specialization
The investigator focuses on evaluating combination therapy approaches in oncology, particularly studying:
- Immunotherapy combinations
- Hormone therapy integration
- Novel therapeutic agents
Their research encompasses both traditional chemotherapy and targeted treatment modalities.
Disease-Specific Expertise
The investigator demonstrates particular interest in hormone-dependent cancers and their treatment pathways, including:
- HR-positive breast cancer
- HER2-negative breast cancer
- Metastatic pancreatic disease
Their work focuses on developing treatment strategies for previously untreated metastatic conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.